Navigation Links
Teriparatide outperforms alendronate in treating steroid-induced osteoporosis
Date:10/28/2009

A recent study determined glucocorticoid-induced osteoporosis (OP) is now treatable with Teriparatide, a synthetic form of the human parathyroid hormone. Researchers found patients with glucocorticoid-induced OP who were treated with teriparatide for 36 months had a greater increase in bone mineral density (BMD) and fewer new vertebral fractures than those treated with alendronate. The findings of this study are published in the November issue of Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR).

Glucocorticoids are steroid hormones that are naturally produced in the body or synthetically created compounds (drugs) used to reduce inflammation. These steroid drugs are used to control inflammation in patients with such autoimmune diseases as rheumatoid arthritis, systemic lupus erythematosus, and Crohn's disease as well as inflammatory conditions such as asthma. Glucocorticoid-induced osteoporosis occurs when patients taking steroid medications such as prednisone, prednisolone, dexamethasone, and cortisone exhibit reduced bone mass and bone strength.

This 36-month, randomized, double-blind, controlled trial, led by Kenneth Saag, M.D., from the University of Alabama, was conducted at 76 centers located in 13 countries. A total of 428 patients between the ages of 22-89 with confirmed OP who had received greater than 5 mg/day of prednisone or equivalent for more than 3 months preceding screening were included. Research measures included changes in lumbar spine and hip bone, BMD, changes in bone biomarkers, fracture incidence, and safety.

Study participants were randomly assigned to receive injectable teriparatide (20 μg/day) plus oral placebo (150 subjects) or oral alendronate (10 mg/day) plus injectable placebo (144 subjects). Supplements of calcium (1,000 mg/day) and vitamin D (800 IU/day) were provided to all study participants. Subjects kept a daily journal to record their steroid use.

Results show at 36 months the BMD for lumbar spine was 11% higher than baseline in the teriparatide group compared with 5.3% in the alendronate group. The BMD (teriparatide versus alendronate) for total hip was 5.2% versus 2.7% and 6.3% versus 3.4% for femoral neck. Researchers also observed fewer vertebral fractures in subjects taking teriparatide (1.7%) than those administered alendronate (7.7%). Higher levels of calcium concentrations were noted in the teriparatide group (21%) than in the alendronate group (7%).

"There is a significant number of individuals who are regularly treated with steroids to control inflammation which puts them at risk for developing osteoporosis. A need for therapies that mitigate this side-effect of steroid use and substantially improves bone mass is vital," commented Dr. Saag. The ACR estimates that diseases commonly treated with (cortico)steroids may affect more than 30 million Americans. "Our research shows that teriparatide is a safe and effective treatment for patients with steroid-induced OA and should be considered as a therapeutic option for those at high risk of bone fracture," recommended Dr. Saag.


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. FDA Approves Expanded Use of Lillys FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
2. Cheap, quick bedside eye movement exam outperforms MRI for diagnosing stroke in patients
3. New heart disease risk score outperforms existing test
4. Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer
5. MedAmerica Reports Solid Growth, Outperforms Industry
6. PET outperforms CT in characterization of lung nodules
7. COURAGE Sub-study: PCI Outperforms Drugs-Only
8. Watson to Distribute Alendronate Tablets
9. Stanford study recommends change in treating pulmonary embolisms
10. Oklahoma scientists discover promising new path for treating traumas
11. Treating ROP in tiny preemies; better glaucoma follow-up in urban clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... organized to provide first-quality education and high-level training standards to an international multidisciplinary ... of eating disorder problems. As a way to further its mission at the ...
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s ... the field of midmarket financial software. , Members of the VAR Stars were selected ... based on revenue and those firms chosen represent a wide range of size and ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... has achieved accreditation for its specialty care services. Albertsons Companies is the ... specialty care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ ...
(Date:1/15/2017)... ... , ... The Gravity Vault Indoor Rock Climbing Gym is excited to announce ... the 14,000+ square foot climbing gym, the owners anticipate to open sometime in February ... and two in New York. With this being its first location in Pennsylvania, The ...
(Date:1/14/2017)... ... January 14, 2017 , ... AgileMinder develops innovative products and ... Emoji Scale is now available on Apple as a fun, free emoji sticker pack ... choosing one of the ten color coded values on The Emoji Scale. , ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Jan. 16, 2017  Rigel Pharmaceuticals (Nasdaq: ... and January 16, 2017 the Compensation Committee of Rigel,s ... options to purchase an aggregate of 214,000 shares of ... granted pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, ... employees entering into employment with Rigel, in accordance with ...
(Date:1/15/2017)... 14, 2017 ImmersiveTouch Inc., the global leader ... announced recent appointments strengthening their Executive Management team.  ... as Chief Executive Officer, Jay Banerjee as ... President of Sales and Jia Luo , PhD ... Mr. Bowman has 20 years experience commercializing ...
(Date:1/13/2017)... 13, 2017 Constant research ongoing in ... collectively contribute to the demand for western blotting technique. The ... of US$ 551.0 Mn by 2016 end. Developing economies in ... lucrative markets for western blotting, whereas North America ... ...
Breaking Medicine Technology: